Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study (Q33751538)

29 July 2017

title

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study (English)

1 reference

29 July 2017

Hiangkiat Tan

1 reference

29 July 2017

Karen Tomic

1 reference

29 July 2017

Dana Hurley

1 reference

29 July 2017

Gregory Daniel

1 reference

29 July 2017

Rich Barron

1 reference

29 July 2017

Jen Malin

1 reference

29 July 2017

language of work or name

English

0 references

publication date

22 November 2010

1 reference

full work available at URL

29 July 2017

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2010.536527

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1185/03007995.2010.536527

Current Medical Research and Opinion

30 August 2024

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

79-86

1 reference

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States)

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Longitudinal data analysis for discrete and continuous outcomes

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Estimating Causal Effects from Large Data Sets Using Propensity Scores

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

Impact of asthma controller medications on clinical, economic, and patient-reported outcomes

30 August 2024

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.536527

30 August 2024

Identifiers

DOI

1 reference

29 July 2017

1 reference